Systemic Immune Activation and Peripheral Blood Lymphocytes during Primary Chemotherapy with the Combination of Doxorubicin and Paclitaxel in Patients with Breast Carcinoma

Pteridines

Touskova Miroslava¹  Vesely Pavel²  Solichova Dagmar³  Hornychova Helena³  Mergancova Jindriska⁴  Vokurkova Doris⁵  Ryska Ales⁶  Urminska Hana⁷  Melichar Bohuslav⁸ 

[1] fax [phone];Departments of Gerontology & Metabolic Care, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Departments of Immunology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Departments of Oncology and Radiotherapy, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Departments of Pathology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Departments of Radiology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Departments of Surgery, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic;Klinika onkologie a radioterapie, Lekarska fakulta Univerzity Karlovy a Fakultni nemocnice, Budova 23, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Tel [phone];

关键词: breast carcinoma;    lymphocytes;    neopterin;    monocytes;    primary chemotherapy;   

DOI  :  10.1515/pteridines.2007.18.1.25

来源: DOAJ

【 摘 要 】

In recent years, there has been interest in the study of alterations of the immune system of breast carcinoma patients undergoing primary chemotherapy. Changes in the phenotype, function of peripheral blood lymphocytes as well as alterations in the release of pro-inflammatory cytokines accompanying the administration of primary chemotherapy have been described. We have investigated urinary neopterin and peripheral blood leukocyte phenotype in 44 breast carcinoma patients treated with the combination of doxorubicin and paclitaxel.

【 授权许可】

Unknown